[go: up one dir, main page]

MX2019003052A - Composiciones para compuestos de agente terapeutico de molecula pequeña. - Google Patents

Composiciones para compuestos de agente terapeutico de molecula pequeña.

Info

Publication number
MX2019003052A
MX2019003052A MX2019003052A MX2019003052A MX2019003052A MX 2019003052 A MX2019003052 A MX 2019003052A MX 2019003052 A MX2019003052 A MX 2019003052A MX 2019003052 A MX2019003052 A MX 2019003052A MX 2019003052 A MX2019003052 A MX 2019003052A
Authority
MX
Mexico
Prior art keywords
therapeutic agent
small molecule
molecule therapeutic
organic acid
compositions
Prior art date
Application number
MX2019003052A
Other languages
English (en)
Inventor
A Watkins Gregory
Original Assignee
Delpor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delpor Inc filed Critical Delpor Inc
Publication of MX2019003052A publication Critical patent/MX2019003052A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición que comprende una suspensión acuosa que comprende un agente terapéutico de molécula pequeña y un ácido orgánico. El agente terapéutico de molécula pequeña es una base y que tiene una solubilidad en agua a temperatura ambiente de menos de aproximadamente 1.0 g/L. El ácido orgánico tiene una solubilidad en agua a temperatura ambiente de entre 0.1 y 10, tiene una masa molar de menos de 500 gramos por mol, y/o mantiene un pH de la suspensión en su ambiente de uso de entre 3.0-6.5. El ácido orgánico mejora la solubilidad del agente terapéutico de molécula pequeña y cuando se presenta en exceso estequiométrico, el ácido orgánico conduce la liberación del agente terapéutico de molécula pequeña en un ambiente amortiguado de uso por periodos prolongados de, por ejemplo, seis meses hasta un año. También se describen dispositivos que comprenden las composiciones y métodos de tratamiento.
MX2019003052A 2016-09-23 2017-09-22 Composiciones para compuestos de agente terapeutico de molecula pequeña. MX2019003052A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662399083P 2016-09-23 2016-09-23
PCT/US2017/053074 WO2018057968A1 (en) 2016-09-23 2017-09-22 Compositions for small molecule therapeutic agent compounds

Publications (1)

Publication Number Publication Date
MX2019003052A true MX2019003052A (es) 2019-11-25

Family

ID=60083440

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003052A MX2019003052A (es) 2016-09-23 2017-09-22 Composiciones para compuestos de agente terapeutico de molecula pequeña.
MX2023003010A MX2023003010A (es) 2016-09-23 2019-03-15 Composiciones para compuestos de agente terapeutico de molecula peque?a.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023003010A MX2023003010A (es) 2016-09-23 2019-03-15 Composiciones para compuestos de agente terapeutico de molecula peque?a.

Country Status (10)

Country Link
US (2) US20190224322A1 (es)
EP (1) EP3515407A1 (es)
JP (3) JP7716175B2 (es)
KR (2) KR102728012B1 (es)
CN (1) CN109890365A (es)
AU (1) AU2017331340B2 (es)
BR (1) BR112019005542A2 (es)
CA (1) CA3037531A1 (es)
MX (2) MX2019003052A (es)
WO (1) WO2018057968A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004538A (zh) * 2018-02-27 2020-11-27 德尔宝股份有限公司 小分子治疗剂化合物的组合物
JP2022546995A (ja) * 2019-08-28 2022-11-10 デルポー・インコーポレイテッド 小分子治療剤化合物のための組成物
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
CN115192548A (zh) * 2021-04-13 2022-10-18 上海博志研新药物技术有限公司 一种布瑞哌唑口溶膜组合物、其制备方法及应用
EP4384256A4 (en) * 2021-08-13 2025-07-02 Mott Corp MEDICATION DELIVERY SET FOR EXTENDED MEDICATION DELIVERY AND ADJUSTABILITY
WO2025101908A1 (en) 2023-11-09 2025-05-15 Delpor, Inc. Method of treatment with risperidone via an implantable subcutaneous device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US7592300B2 (en) * 2003-11-24 2009-09-22 The Dial Corporation Antimicrobial compositions containing an aromatic carboxylic acid and a hydric solvent
AR048272A1 (es) * 2004-03-18 2006-04-12 Lek Pharmaceuticals Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
PL377084A1 (pl) * 2005-09-15 2007-03-19 Koźluk Tomasz Nobilus Ent Nowe związki olanzapiny i sposób ich wytwarzania
US8242269B2 (en) * 2007-10-09 2012-08-14 Cipla Limited Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
CA3037010A1 (en) * 2009-01-20 2010-07-29 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Cente Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
EP2405967B1 (en) 2009-03-12 2020-09-23 Delpor, Inc. Implantable device for long-term delivery of drugs
WO2010146872A1 (ja) * 2009-06-19 2010-12-23 株式会社メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
AU2010265863C1 (en) * 2009-06-26 2012-11-01 Taris Biomedical Llc Implantable drug delivery devices and methods of making the same
PT2394663T (pt) * 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
KR101408370B1 (ko) * 2012-06-26 2014-06-18 주식회사지씨비 아리피프라졸-유기산 공결정을 함유하는 제제 및 이의 제조 방법
JP6538559B2 (ja) * 2012-09-28 2019-07-03 デルポー，インコーポレイティド 抗精神病薬の徐放のための装置及び方法
CN106474058B (zh) * 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂

Also Published As

Publication number Publication date
US20250009886A1 (en) 2025-01-09
EP3515407A1 (en) 2019-07-31
KR102728012B1 (ko) 2024-11-11
MX2023003010A (es) 2023-04-10
WO2018057968A1 (en) 2018-03-29
JP7716175B2 (ja) 2025-07-31
CA3037531A1 (en) 2018-03-29
AU2017331340B2 (en) 2023-09-28
JP7731333B2 (ja) 2025-08-29
CN109890365A (zh) 2019-06-14
BR112019005542A2 (pt) 2019-06-18
JP2025106324A (ja) 2025-07-15
KR20190066608A (ko) 2019-06-13
JP2019529564A (ja) 2019-10-17
US20190224322A1 (en) 2019-07-25
JP2022188046A (ja) 2022-12-20
AU2017331340A1 (en) 2019-04-11
KR20230093349A (ko) 2023-06-27

Similar Documents

Publication Publication Date Title
MX2019003052A (es) Composiciones para compuestos de agente terapeutico de molecula pequeña.
AR072224A1 (es) Derivados de pirimidona sustituidos
MX386676B (es) Herbicida para despues del brote
MX359517B (es) Composiciones, formulaciones y metodos de compuestos lipidicos modificadores de respuestas inmunitaria.
BR112014025564B8 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma
CL2019002677A1 (es) Composición adhesiva y método de preparación de la misma.
MX2023010248A (es) Composiciones de acido ascorbico estables y metodos de uso de las mismas.
NZ714558A (en) Formulation comprising a hypolipidemic agent
PH12016500146B1 (en) Plant disease control composition and its use
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
PH12016502100A1 (en) Liquid formulation comprising gm-csf neutralizing compound
BR112015018547A2 (pt) microbiocidas
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
BR112015023829A2 (pt) composto de amidina e seu uso
AR077371A1 (es) DERIVADOS DE PIRAZOL, SU PREPARACIoN Y SU APLICACIoN EN LA TERAPIA DEL CÁNCER
EA200800777A1 (ru) Применение сложных эфиров молочной кислоты для улучшения действия пестицидов
PE20142421A1 (es) Fenilimidazopirazoles sustituidos y su uso
BR112018008951A8 (pt) composto de aminoácido, complexo, mistura, fertilizante, e, agente regulador de crescimento de plantas.
MX365971B (es) Composiciones para el cuidado bucal.
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica
EA202090750A1 (ru) Производные глюконовой кислоты для применения в лечении и/или предупреждении инфекций, вызываемых микроорганизмами
CL2017001039A1 (es) Composiciones anti-transpirantes anhidras
EA201792122A1 (ru) Кристаллическое соединение как ингибитор фермента семикарбазидчувствительной аминоксидазы (ssao)
AR112040A1 (es) Sal de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2-metoxifenil}amino)-1-metil-4,5-dihidro-1h-pirazolo[4,3-h]quinazolina-3-carboxamida, su preparación, y las formulaciones que la contienen
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica